Vaxcyte, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Operating expenses | $923.7M | $569.5M | $468.0M | $232.3M | $103.7M |
| Cash from operations | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Capital expenditure | $13.7M | $22.4M | $16.1M | $5.8M | $6.6M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Impairments | — | $0 | $0 | $200,000 | $0 |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
Shares outstanding 144.4M · Free float 95.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.